Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide

Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide Mohamad A. Hussein Oncologist 2003; 8(Suppl 3): 39-45 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Discuss the current issues surrounding the treatment of multiple myeloma. Describe how treatment modifications have improved the tolerability and efficacy of this multiple myeloma therapy. Explain recent treatment advances in this disease. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Click Here to return to the complete course listing of Penetrating Insights: Crossing the Cancer Cell Membrane to Improve Clinical Outcomes.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Dec. 12, 2003 Most Recent Review: June 10, 2005* Most Recent Update: Dec. 12, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.